On 6 October 2025, Hikma Pharmaceuticals and Celltrion Inc, announced that they have entered exclusive licensing agreements for 6 biosimilars, across the Middle East and North Africa (MENA) region. The identities of the biosimilars have not yet been disclosed but they are said to treat “key therapeutic areas”, including allergic diseases, ophthalmology, skeletal-related disorders, immune diseases and oncology.
Under the agreements, Hikma holds the exclusive commercialisation rights across all MENA markets, while Celltrion is responsible for the development, manufacturing and supply of the biosimilars.
Hikma and Celltrion have previously partnered in relation to the commercialisation of multiple biosimilars in MENA, including a January 2023 deal regarding Vegzelma® (CT-P16, biosimilar bevacizumab), 2022 deals for CT-P43 (biosimilar ustekinumab) and Yuflyma™ (biosimilar adalimumab), and agreements for Truxima® (biosimilar rituximab), Remsima®/Remsima® SC (biosimilar infliximab) and Herzuma® (biosimilar trastuzumab).
There have been a number of recent announcements regarding commercialisation of biosimilars in MENA, with deals for Polpharma & MS Pharma in September 2025 (biosimilar guselkumab (PB019), ocrelizumab (PB018) and vedolizumab (PB016)), Bio-Thera & Jamjoom Pharma in September 2025 (biosimilar secukinumab (BAT2306)), and Kashiv & MS Pharma in August 2025 (biosimilar omalizumab (ADL-018)).